Showing results (51-60 of 141) with videos related to
Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancerAlex A Adjei, Ann Mauer, Laura Bruzek, et al.Investigational New Drugs|June 25, 2010
A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinomaManish A Shah, Derek G Power, Hedy L Kindler, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumorsWells A Messersmith, Sharyn D Baker, Lance Lassiter, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk featuresJudith E Karp, B Douglas Smith, Ivana Gojo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2011
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemiasJeffrey E Lancet, Vu H Duong, Elliott F Winton, et al.Anti-Cancer Drugs|February 16, 2005
Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium TrialPrimo N Lara, Lisa Y Law, John J Wright, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2006
Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamideJoseph A Sparano, Stacy Moulder, Aslamuzzaman Kazi, et al.Cancer Chemotherapy and Pharmacology|August 2, 2013
Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genesJill M Kolesar, Anne M Traynor, Kyle D Holen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumorsIgnacio Duran, Sebastien J Hotté, Holger Hirte, et al.Clinical Colorectal Cancer|February 12, 2014
A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancersCrystal S Denlinger, Neal J Meropol, Tianyu Li, et al.Pageof 15